Cabotegravir long-acting: Clinical Trials

2 recruiting, 1 active not recruiting. 2 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Active not recruiting 1, Recruiting 1
Phase 2	1	Recruiting 1

Follow Cabotegravir long-acting: new trials by email Literature Review of Cabotegravir long-acting trials Research Report on Cabotegravir long-acting

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1 Oral CAB, IM CAB LA - HIV Infections	Phase 1 / Phase 2	Recruiting	ViiV Healthcare	44	2026-04-15	2026-05-19
A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV Cabotegravir long-acting, Lenacapavir long-acting - HIV Infections	Phase 1	Active not recruiting	ViiV Healthcare	65	2025-04-22	2025-11-28
PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa. Cabotegravir long-acting, Tenofovir emtricitabine, Dapivirine containing vaginal ring - HIV Infection, Sexual and Reproductive Health		Recruiting	Desmond Tutu HIV Foundation	1800	2024-02-13	2025-02-04

Conditions studied

HIV Infections (3)  ·  Coitus (1)  ·  Injection Site Reaction (1)

Sponsors

ViiV Healthcare (2)  ·  Desmond Tutu HIV Foundation (1)

Countries

South Africa (2)  ·  United States (1)

Results publications

PMID 40993613